Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07917429

Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC

Sponsor: Fujian Medical University Union Hospital

View on ClinicalTrials.gov

Summary

This is a prospective, observational, multicenter cohort study. Subjects will be divided into the Panitumumab N01 group (experimental group) and the cetuximab or cetuximab N01 group (control group) according to the treatment they actually receive. Both groups will receive FOLFOX chemotherapy. Real-world follow-up data will be used to comprehensively evaluate clinical efficacy, safety and health economic outcomes between the two groups. No fewer than 610 patients planned to receive first-line treatment for colorectal cancer with FOLFOX combined with Panitumumab N01 or cetuximab/cetuximab N01 will be enrolled (305 patients in the cetuximab/cetuximab N01 arm and 305 patients in the Panitumumab N01 arm). After enrollment, medical records of participants will be collected, including baseline characteristics, laboratory test results, radiological assessments, medication history and survival status, with follow-up continuing until March 2030. Adverse events will be collected up to 28 ± 7 days after the last dose to capture potential safety events. Follow-up schedule: survival will be confirmed by telephone monthly in accordance with routine clinical practice at local sites; clinical follow-up every 3 months is recommended for patients discontinuing treatment for reasons other than disease progression. This study will not alter the established clinical decisions of treating physicians or impose additional treatment risks on patients. All treatment regimens will be administered in accordance with clinical guideline recommendations and individual patient clinical circumstances.

Official title: A Real-World Study of FOLFOX Combined With Panitumumab N01 Versus Cetuximab as First-Line Treatment for RAS Wild-Type Metastatic Colorectal Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

610

Start Date

2027-01-01

Completion Date

2030-06-01

Last Updated

2026-11-04

Healthy Volunteers

No

Interventions

DRUG

Panitumumab N01

Panitumumab N01 plus FOLFOX

DRUG

Cetuximab (EGFR inhibitor)

cetuximab or cetuximab N01 plus FOLFOX

Locations (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, China